SCLC
MCID: SML033
MIFTS: 54

Small Cell Cancer of the Lung, Somatic (SCLC) malady

Categories: Genetic diseases, Respiratory diseases, Rare diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Small Cell Cancer of the Lung, Somatic

Aliases & Descriptions for Small Cell Cancer of the Lung, Somatic:

Name: Small Cell Cancer of the Lung, Somatic 54 13
Small Cell Lung Cancer 56 29 52
Small Cell Carcinoma of Lung 12 69
Lung Small Cell Carcinoma 12 14
Lung Oat Cell Carcinoma 12 14
Carcinoma, Small Cell 42 69
Sclc 12 56
Small Cell Neuroendocrine Carcinoma of Lung 12
Poorly Differentiated Endocrine Neoplasm 12
Small Cell Cancer of the Lung 54
Oat Cell Carcinoma of Lung 12
Small Cell Lung Carcinoma 42
Oat Cell Carcinoma 12
Carcinoma Oat Cell 52

Characteristics:

Orphanet epidemiological data:

56
small cell lung cancer
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

HPO:

32
small cell cancer of the lung, somatic:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare respiratory diseases


External Ids:

OMIM 54 182280
Disease Ontology 12 DOID:5409 DOID:5411
NCIt 47 C4917 C3915
Orphanet 56 ORPHA70573
ICD10 via Orphanet 34 C34.9

Summaries for Small Cell Cancer of the Lung, Somatic

Disease Ontology : 12 A lung carcinoma that has material basis in primitive-appearing cells that are smaller than normal cells.

MalaCards based summary : Small Cell Cancer of the Lung, Somatic, also known as small cell lung cancer, is related to lung cancer and gallbladder small cell carcinoma, and has symptoms including neoplasm of the lung An important gene associated with Small Cell Cancer of the Lung, Somatic is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Small cell lung cancer and Circadian rythm related genes. The drugs Abraxane and Alimta have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and testes, and related phenotypes are Increased viability with nutlin-3 and behavior/neurological

Description from OMIM: 182280

Related Diseases for Small Cell Cancer of the Lung, Somatic

Diseases related to Small Cell Cancer of the Lung, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 193)
id Related Disease Score Top Affiliating Genes
1 lung cancer 11.3
2 gallbladder small cell carcinoma 11.0
3 esophagus small cell carcinoma 11.0
4 lung combined type small cell carcinoma 10.9
5 peroneal nerve paralysis 10.4 CHGA SYP
6 blood group incompatibility 10.4 ENO2 SYP TP53
7 prolactin producing pituitary tumor 10.4 CHGA ENO2 SYP
8 burning mouth syndrome type 3 10.4 POMC SST
9 renal hypoplasia, bilateral 10.4 POMC SST
10 gallbladder pleomorphic giant cell adenocarcinoma 10.4 ENO2 SYP TP53
11 adult epithelioid sarcoma 10.4 ENO2 SYP TP53
12 diffuse cutaneous mastocytosis 10.4 AVP CHGA SYP
13 gliofibroma 10.4 CHGA ENO2 SYP
14 brain oligodendroglioma 10.4 SYP TP53 TP73
15 kidney disease 10.4 NKX2-1 SYP TP53
16 brain stem astrocytic neoplasm 10.4 CHGA SYP TP53
17 ampullary signet ring cell adenocarcinoma 10.4 ENO2 NCAM1 SYP
18 villous adenocarcinoma 10.4 CHGA NKX2-1 SYP
19 bone deterioration disease 10.4 NKX2-1 SYP TP53
20 acalculous cholecystitis 10.4 AVP CHGA SYP
21 piussan lenaerts mathieu syndrome 10.4 CHGA ENO2 SYP
22 childhood central nervous system primitive neuroectodermal neoplasm 10.4 ENO2 SYP TP53
23 multiple chemical sensitivity 10.4 ENO2 SYP TP53
24 pediculus humanus corporis infestation 10.4 CHGA ENO2 SYP
25 vagneur triolle ripert syndrome 10.4 CEACAM5 CHGA
26 cavernous hemangioma of face 10.4 CHGA NKX2-1 SYP
27 gastrointestinal system benign neoplasm 10.4 CHGA ENO2 NKX2-1
28 thymus squamous cell carcinoma 10.4 CHGA SYP TP53
29 barre-lieou syndrome 10.4 ASCL1 CHGA SYP
30 ampulla of vater mucinous adenocarcinoma 10.4 CHGA ENO2 SYP
31 syringomelia hyperkeratosis 10.4 AVP CHGA POMC
32 gonococcal seminal vesiculitis 10.4 AVP CALCA POMC
33 water-clear cell adenoma 10.4 POMC SST
34 congenital muscular dystrophy with hyperlaxity 10.4 ENO2 NKX2-1 SYP
35 granulomatous myositis 10.4 ENO2 SYP TP53
36 monkeypox 10.4 AVP KIT SYP
37 bone marrow cancer 10.4 CHGA NKX2-1 SYP
38 granulocytopenia 10.4 CHGA ENO2 KRT20
39 childhood medulloblastoma 10.4 ENO2 SYP TP53
40 inner ear cancer 10.4 CHGA SYP TP53
41 cavernous hemangioma of colon 10.4 ENO2 GRP NCAM1
42 uterine corpus sarcoma 10.4 ENO2 NCAM1
43 paraphimosis 10.4 KRT20 SYP TP53
44 chromophil adenoma of the kidney 10.4 ENO2 KRT20 NKX2-1
45 breast pericanalicular fibroadenoma 10.4 KRT20 NKX2-1 TP53
46 ovarian embryonal carcinoma 10.4 KIT NKX2-1 TP53
47 malignant mediastinal neurogenic neoplasm 10.4 CEACAM5 TP53
48 breast squamous cell carcinoma 10.4 ENO2 SYP TP53
49 lung occult small cell carcinoma 10.4 CALCA SST TP53
50 brain ependymoma 10.4 CALCA ENO2 SST

Graphical network of the top 20 diseases related to Small Cell Cancer of the Lung, Somatic:



Diseases related to Small Cell Cancer of the Lung, Somatic

Symptoms & Phenotypes for Small Cell Cancer of the Lung, Somatic

Symptoms by clinical synopsis from OMIM:

182280

Clinical features from OMIM:

182280

Human phenotypes related to Small Cell Cancer of the Lung, Somatic:

32
id Description HPO Frequency HPO Source Accession
1 neoplasm of the lung 32 HP:0100526

GenomeRNAi Phenotypes related to Small Cell Cancer of the Lung, Somatic according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with nutlin-3 GR00123-A 8.62 MYCL TP53

MGI Mouse Phenotypes related to Small Cell Cancer of the Lung, Somatic:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 ASCL1 AVP CKB ENO2 GRP KIT
2 mortality/aging MP:0010768 10.13 TP73 MYCL NCAM1 NKX2-1 POMC RB1
3 nervous system MP:0003631 10.07 NCAM1 NKX2-1 POMC RB1 SST SYP
4 no phenotypic analysis MP:0003012 9.76 ASCL1 AVP KIT NKX2-1 POMC RB1
5 normal MP:0002873 9.61 ASCL1 AVP KIT MYCL NKX2-1 RB1
6 pigmentation MP:0001186 9.02 ASCL1 KIT POMC RB1 TP53

Drugs & Therapeutics for Small Cell Cancer of the Lung, Somatic

FDA approved drugs:

(show all 19)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 46 PACLITAXEL Celgene Approved October 2012
2
Alimta 17 46 PEMETREXED (also Pemetrexed Disodium) Eli Lilly Approved February 2004
3
Avastin 17 46 BEVACIZUMAB Genentech Approved July 2009
4
Gemzar 17 46 GEMCITABINE HYDROCHLORIDE Eli Lilly Approved May 1996
5
Gilotrif 17 46 AFATINIB DIMALEATE Boehringer Ingelheim Approved July 2013
6
Hycamtin 17 46 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham Approved October 2007/Approved May 1996
7
Iressa 17 46 GEFITINIB AstraZeneca Approved May 2003
8
Neutroval 17 tbo-filgrastim Teva Pharmaceutical Approved August 2012
9
Opdivo 17 46 NIVOLUMAB Bristol-Myers Squibb Approved March 2015/ Approved December 2014, Approved March 2015
10
Photofrin 17 PORFIMER SODIUM QLT Approved January 1998
11
Tarceva 17 46 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals Approved November, 2004
12
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer Approved May 1996
13
Xalkori 17 46 CRIZOTINIB Pfizer Approved August of 2011
14
Xgeva 17 46 DENOSUMAB Amgen Approved June 2013/ Approved November 2010
15
Zometa 17 46 ZOLEDRONIC ACID Novartis Approved August 2001/ Approved February 2002
16
Zykadia 17 46 CERITINIB Novartis Approved April 2014
17
Alecensa 17 ALECTINIB HYDROCHLORIDE Roche Approved December 2015
18
Portazza 17 NECITUMUMAB Eli Lilly Approved November 2015
19
Tagrisso 17 OSIMERTINIB MESYLATE AstraZeneca Approved November 2015

Drugs for Small Cell Cancer of the Lung, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 730)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
2
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
3
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 150399-23-8, 137281-23-3 446556 60843
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
6
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
7
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
8
Fluorouracil Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-21-8 3385
9
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
10
Trioxsalen Approved Phase 4,Phase 2,Phase 1 3902-71-4 5585
11
Levoleucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 68538-85-2
12
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
13
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
14
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 184475-35-2 123631
15
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
16
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
17
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
18
Nicotine Approved Phase 4,Phase 3,Phase 1 54-11-5 942 89594
19
Armodafinil Approved, Investigational Phase 4,Phase 2 112111-43-0
20
Modafinil Approved, Investigational Phase 4,Phase 2 68693-11-8 4236
21
Menthol Approved Phase 4,Phase 1,Phase 2 2216-51-5 16666
22
Edetic Acid Approved, Vet_approved Phase 4,Phase 2,Early Phase 1 60-00-4, 62-33-9 6049
23
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
24
Technetium tc 99m sulfur colloid Approved Phase 4
25
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
26
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59-30-3 6037
27
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
28
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7689-03-4
29
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
30 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Diphosphonates Phase 4,Phase 3,Phase 2
37 Folic Acid Antagonists Phase 4,Phase 3,Phase 1,Phase 2
38 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1
42 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
49 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 2675)
id Name Status NCT ID Phase
1 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4
2 An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy Approved for marketing NCT02589717 Phase 4
3 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
5 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4
6 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4
7 A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients Completed NCT01020786 Phase 4
8 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Recruiting NCT02348450 Phase 4
9 VISmodegib for ORbital and Periocular Basal Cell Carcinoma Recruiting NCT02436408 Phase 4
10 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Recruiting NCT02015650 Phase 4
11 TACE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma Recruiting NCT02704130 Phase 4
12 Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer Recruiting NCT02916745 Phase 4
13 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4
14 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
15 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Active, not recruiting NCT02151149 Phase 4
16 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Active, not recruiting NCT02287675 Phase 4
17 Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy Suspended NCT01720901 Phase 4
18 Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load Terminated NCT00977054 Phase 4
19 A Post Marketing Surveillance As Required By Philippine Food And Drug Administration Withdrawn NCT01781442 Phase 4
20 Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient Unknown status NCT00826644 Phase 3
21 A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer Unknown status NCT01731548 Phase 2, Phase 3
22 STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study Unknown status NCT00526396 Phase 3
23 Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer Unknown status NCT00011921 Phase 3
24 Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer Unknown status NCT00003696 Phase 3
25 Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Unknown status NCT00003606 Phase 3
26 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer Unknown status NCT00002858 Phase 3
27 Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Unknown status NCT01555710 Phase 3
28 A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage Unknown status NCT00168896 Phase 2, Phase 3
29 Study of Picoplatin Efficacy After Relapse Unknown status NCT00465491 Phase 3
30 Exercise for Patients With Renal Cell Cancer Receiving Sunitinib Unknown status NCT00869011 Phase 3
31 Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) Unknown status NCT01830231 Phase 2, Phase 3
32 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Unknown status NCT00867347 Phase 3
33 Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer Unknown status NCT00006030 Phase 3
34 Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer) Unknown status NCT00079027 Phase 3
35 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
36 Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Unknown status NCT00551733 Phase 3
37 Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer Unknown status NCT01579188 Phase 3
38 Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer Unknown status NCT00030641 Phase 2, Phase 3
39 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
40 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
41 Evaluation of Stents to Open Restricted Airways in Patients With Centrally Placed Non-small Cell Lung Cancer Unknown status NCT01003522 Phase 3
42 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
43 Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00008281 Phase 3
44 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3
45 Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer Unknown status NCT00365105 Phase 3
46 CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL Unknown status NCT00576225 Phase 3
47 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3
48 Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
49 The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy Completed NCT00270166 Phase 3
50 Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer Completed NCT00658580 Phase 3

Search NIH Clinical Center for Small Cell Cancer of the Lung, Somatic

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: carcinoma, small cell

Genetic Tests for Small Cell Cancer of the Lung, Somatic

Genetic tests related to Small Cell Cancer of the Lung, Somatic:

id Genetic test Affiliating Genes
1 Small Cell Lung Cancer 29

Anatomical Context for Small Cell Cancer of the Lung, Somatic

MalaCards organs/tissues related to Small Cell Cancer of the Lung, Somatic:

39
Lung, Bone, Testes, Breast, Endothelial, T Cells, Prostate

Publications for Small Cell Cancer of the Lung, Somatic

Variations for Small Cell Cancer of the Lung, Somatic

ClinVar genetic disease variations for Small Cell Cancer of the Lung, Somatic:

6 (show top 50) (show all 86)
id Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
3 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
4 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
5 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
6 RB1 NM_000321.2(RB1): c.2242G> T (p.Glu748Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121913297 GRCh37 Chromosome 13, 49039164: 49039164
7 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
8 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
9 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
10 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
11 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
12 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
13 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
14 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
15 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
16 PTEN NM_000314.6(PTEN): c.389G> C (p.Arg130Pro) single nucleotide variant Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
17 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
18 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Likely pathogenic rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
19 TP53 NM_000546.5(TP53): c.487T> G (p.Tyr163Asp) single nucleotide variant Likely pathogenic rs786203436 GRCh37 Chromosome 17, 7578443: 7578443
20 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
21 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
22 TP53 NM_000546.5(TP53): c.743G> T (p.Arg248Leu) single nucleotide variant Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
23 TP53 NM_000546.5(TP53): c.587G> C (p.Arg196Pro) single nucleotide variant Likely pathogenic rs483352697 GRCh37 Chromosome 17, 7578262: 7578262
24 TP53 NM_000546.5(TP53): c.577C> T (p.His193Tyr) single nucleotide variant Likely pathogenic rs876658468 GRCh37 Chromosome 17, 7578272: 7578272
25 TP53 NM_000546.5(TP53): c.743G> C (p.Arg248Pro) single nucleotide variant Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
26 TP53 NM_000546.5(TP53): c.643A> G (p.Ser215Gly) single nucleotide variant Likely pathogenic rs886039484 GRCh37 Chromosome 17, 7578206: 7578206
27 TP53 NM_000546.5(TP53): c.731G> A (p.Gly244Asp) single nucleotide variant Likely pathogenic rs985033810 GRCh37 Chromosome 17, 7577550: 7577550
28 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
29 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
30 TP53 NM_001126112.2(TP53): c.746G> C (p.Arg249Thr) single nucleotide variant Likely pathogenic rs587782329 GRCh37 Chromosome 17, 7577535: 7577535
31 TP53 NM_001126112.2(TP53): c.518T> G (p.Val173Gly) single nucleotide variant Likely pathogenic rs1057519747 GRCh37 Chromosome 17, 7578412: 7578412
32 TP53 NM_001126113.2(TP53): c.518T> C (p.Val173Ala) single nucleotide variant Likely pathogenic rs1057519747 GRCh37 Chromosome 17, 7578412: 7578412
33 PIK3CA NM_006218.3(PIK3CA): c.1624G> C (p.Glu542Gln) single nucleotide variant Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
34 RB1 NM_000321.2(RB1): c.2117G> T (p.Cys706Phe) single nucleotide variant Likely pathogenic rs121913295 GRCh37 Chromosome 13, 49037877: 49037877
35 B2M NM_004048.2(B2M): c.3G> A (p.Met1Ile) single nucleotide variant Likely pathogenic rs1057519877 GRCh37 Chromosome 15, 45003747: 45003747
36 B2M NM_004048.2(B2M): c.1A> G (p.Met1Val) single nucleotide variant Likely pathogenic rs1023835002 GRCh37 Chromosome 15, 45003745: 45003745
37 B2M NM_004048.2(B2M): c.1A> T (p.Met1Leu) single nucleotide variant Likely pathogenic rs1023835002 GRCh37 Chromosome 15, 45003745: 45003745
38 B2M NM_004048.2(B2M): c.2T> C (p.Met1Thr) single nucleotide variant Likely pathogenic rs1057519879 GRCh37 Chromosome 15, 45003746: 45003746
39 B2M NM_004048.2(B2M): c.2T> G (p.Met1Arg) single nucleotide variant Likely pathogenic rs1057519879 GRCh37 Chromosome 15, 45003746: 45003746
40 PIK3CA NM_006218.3(PIK3CA): c.1625A> C (p.Glu542Ala) single nucleotide variant Likely pathogenic rs1057519927 GRCh37 Chromosome 3, 178936083: 178936083
41 PIK3CA NM_006218.3(PIK3CA): c.1625A> T (p.Glu542Val) single nucleotide variant Likely pathogenic rs1057519927 GRCh37 Chromosome 3, 178936083: 178936083
42 PIK3CA NM_006218.3(PIK3CA): c.1625A> G (p.Glu542Gly) single nucleotide variant Likely pathogenic rs1057519927 GRCh37 Chromosome 3, 178936083: 178936083
43 PTEN NM_000314.6(PTEN): c.389G> T (p.Arg130Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
44 TP53 NM_001126113.2(TP53): c.857A> G (p.Glu286Gly) single nucleotide variant Likely pathogenic rs1057519985 GRCh37 Chromosome 17, 7577081: 7577081
45 TP53 NM_001126117.1(TP53): c.460G> C (p.Glu154Gln) single nucleotide variant Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
46 TP53 NM_001126117.1(TP53): c.461A> T (p.Glu154Val) single nucleotide variant Likely pathogenic rs1057519985 GRCh37 Chromosome 17, 7577081: 7577081
47 TP53 NM_000546.5(TP53): c.857A> C (p.Glu286Ala) single nucleotide variant Likely pathogenic rs1057519985 GRCh37 Chromosome 17, 7577081: 7577081
48 TP53 NM_001126113.2(TP53): c.730G> T (p.Gly244Cys) single nucleotide variant Likely pathogenic rs1057519989 GRCh37 Chromosome 17, 7577551: 7577551
49 TP53 NM_001126116.1(TP53): c.334G> A (p.Gly112Ser) single nucleotide variant Likely pathogenic rs1057519989 GRCh37 Chromosome 17, 7577551: 7577551
50 TP53 NM_001126118.1(TP53): c.614G> T (p.Gly205Val) single nucleotide variant Likely pathogenic rs985033810 GRCh37 Chromosome 17, 7577550: 7577550

Copy number variations for Small Cell Cancer of the Lung, Somatic from CNVD:

7 (show top 50) (show all 515)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 15909 1 120235683 147296355 Substitutions and indels small cell lung cancer
2 18774 1 147306435 159745095 Substitutions and indels small cell lung cancer
3 21590 1 159753915 159864147 Substitutions and indels small cell lung cancer
4 21631 1 159879159 167481135 Substitutions and indels small cell lung cancer
5 22562 1 167488767 167515635 Substitutions and indels small cell lung cancer
6 22575 1 167524383 182844003 Substitutions and indels small cell lung cancer
7 22643 1 16801095 16840107 Substitutions and in dels small cell lung cancer
8 22724 1 16861959 29150031 Substitutions and in dels small cell lung cancer
9 24621 1 182849019 182888703 Substitutions and indels small cell lung cancer
10 24623 1 182893695 194979795 Substitutions and indels small cell lung cancer
11 25853 1 194993223 195074031 Substitutions and indels small cell lung cancer
12 25942 1 195088143 205083387 Substitutions and indels small cell lung cancer
13 27160 1 205088907 205109547 Substitutions and indels small cell lung cancer
14 27163 1 205114395 208124379 Substitutions and indels small cell lung cancer
15 27411 1 208129227 208155879 Substitutions and indels small cell lung cancer
16 27424 1 208162923 222138663 Substitutions and indels small cell lung cancer
17 28412 1 222150063 222281979 Substitutions and indels small cell lung cancer
18 28435 1 222297471 247249719 Substitutions and indels small cell lung cancer
19 31650 1 29155527 30043083 Substitutions and in dels small cell lung cancer
20 31718 1 30048807 41173191 Substitutions and in dels small cell lung cancer
21 32828 1 39746 16783059 Substitutions and in dels small cell lung cancer
22 33011 1 41174800 41175800 Intrachromosomal rea rrangement small cell lung cancer
23 33013 1 41178543 42371163 Substitutions and in dels small cell lung cancer
24 33099 1 42374208 42375208 Intrachromosomal rea rrangement small cell lung cancer
25 33100 1 42376011 42579327 Substitutions and in dels small cell lung cancer
26 33116 1 42583395 42584395 Intrachromosomal rea rrangement small cell lung cancer
27 33117 1 42584427 44255643 Substitutions and in dels small cell lung cancer
28 33294 1 44259752 44260752 Intrachromosomal rea rrangement small cell lung cancer
29 33295 1 44260511 44261511 Intrachromosomal rea rrangement small cell lung cancer
30 33296 1 44260527 44275323 Substitutions and in dels small cell lung cancer
31 33300 1 44279330 44280330 Intrachromosomal rea rrangement small cell lung cancer
32 33301 1 44279742 44280742 Intrachromosomal rea rrangement small cell lung cancer
33 33302 1 44280303 48578211 Substitutions and in dels small cell lung cancer
34 33819 1 48580747 48581747 Intrachromosomal rea rrangement small cell lung cancer
35 33821 1 48583227 51275739 Substitutions and in dels small cell lung cancer
36 33980 1 51279608 51280608 Intrachromosomal rea rrangement small cell lung cancer
37 33981 1 51281079 54467547 Substitutions and in dels small cell lung cancer
38 34296 1 54469360 54470360 Intrachromosomal rea rrangement small cell lung cancer
39 34297 1 54473247 54557103 Substitutions and in dels small cell lung cancer
40 34301 1 54561497 54562497 Intrachromosomal rea rrangement small cell lung cancer
41 34302 1 54562083 54649251 Substitutions and in dels small cell lung cancer
42 34322 1 54652634 54653634 Intrachromosomal rea rrangement small cell lung cancer
43 34323 1 54654159 57627915 Substitutions and in dels small cell lung cancer
44 34908 1 57632775 57657135 Substitutions and in dels small cell lung cancer
45 34910 1 57661947 72536187 Substitutions and in dels small cell lung cancer
46 36221 1 72541191 72583059 Substitutions and in dels small cell lung cancer
47 36257 1 72587919 85749039 Substitutions and in dels small cell lung cancer
48 37122 1 85755495 85774959 Substitutions and in dels small cell lung cancer
49 37129 1 85779879 120230763 Substitutions and in dels small cell lung cancer
50 41421 10 17866791 18173655 Substitutions and in dels small cell lung cancer

Expression for Small Cell Cancer of the Lung, Somatic

Search GEO for disease gene expression data for Small Cell Cancer of the Lung, Somatic.

Pathways for Small Cell Cancer of the Lung, Somatic

Pathways related to Small Cell Cancer of the Lung, Somatic according to KEGG:

37
id Name Kegg Source Accession
1 Small cell lung cancer hsa05222

Pathways related to Small Cell Cancer of the Lung, Somatic according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
2 11.68 AVP CALCA ENO2 NCAM1 NKX2-1 POMC
3 11.47 ASCL1 AVP SST TP73
4 11.34 ASCL1 NCAM1 SYP

GO Terms for Small Cell Cancer of the Lung, Somatic

Cellular components related to Small Cell Cancer of the Lung, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.35 ASCL1 CALCA CKB ENO2 SST
2 secretory granule GO:0030141 9.33 AVP CHGA POMC
3 extracellular space GO:0005615 9.28 AVP CALCA CHGA CKB ENO2 GRP

Biological processes related to Small Cell Cancer of the Lung, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.77 NCAM1 RB1 TOP1 TP53 TP73
2 regulation of blood pressure GO:0008217 9.58 CALCA CHGA POMC
3 forebrain neuron differentiation GO:0021879 9.46 ASCL1 NKX2-1
4 mitotic G1 DNA damage checkpoint GO:0031571 9.43 TP53 TP73
5 regulation of mitotic cell cycle GO:0007346 9.43 ASCL1 RB1 TP73
6 mast cell chemotaxis GO:0002551 9.32 CHGA KIT
7 positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway GO:1900738 9.16 CHGA GRP
8 cerebral cortex GABAergic interneuron differentiation GO:0021892 8.96 ASCL1 NKX2-1
9 mast cell cytokine production GO:0032762 8.62 CHGA KIT

Molecular functions related to Small Cell Cancer of the Lung, Somatic according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.43 CALCA CEACAM5 RB1 SYP TP53 TP73
2 hormone activity GO:0005179 8.92 AVP CALCA POMC SST

Sources for Small Cell Cancer of the Lung, Somatic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....